Business context and reporting period
Entity mismatch: The request identifies Rocket Pharmaceuticals, Inc., but the supplied 10-K is for Inotek Pharmaceuticals Corporation (NASDAQ: ITEK). This summary covers Inotek’s fiscal year ended December 31, 2016, not a standalone fourth-quarter report. Inotek was a clinical-stage ophthalmology company developing trabodenoson for glaucoma; it had no approved products or product revenue.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $32.0 million | $12.6 million |
| General and administrative expense | $9.9 million | $7.8 million |
| Operating loss | $41.9 million | $20.4 million |
| Net loss | $42.9 million | $68.0 million |
| Net loss per share | $1.60 | $3.72 |
| Cash used in operating activities | $37.3 million | $17.4 million |
| Cash and cash equivalents | $29.8 million | $80.0 million |
| Short-term investments | $96.7 million | $31.2 million |
| Convertible notes, net carrying value | $49.0 million | None |
At year-end, cash and short-term investments totaled $126.5 million; management estimated funding would support operations into 2019. The 2021 Convertible Notes have $52.0 million principal, bear 5.75% interest, and mature August 1, 2021. The filing reports no meaningful operating margins because the company had no revenue. No dividend was paid or expected in the foreseeable future.
Material changes versus the prior year
- R&D expense rose $19.4 million, principally with the monotherapy Phase 3 program and the FDC Phase 2 program; operating loss more than doubled.
- Operating cash use increased by $19.9 million. Cash declined, while short-term investments grew, reflecting investment of available funds.
- Net loss narrowed by $25.1 million, despite higher operating losses. A major factor was the absence of the 2015 noncash $42.8 million loss on the fair value of the 2020 Convertible Notes derivative; 2015 also included a $4.4 million debt-extinguishment loss.
- In 2016, the company issued $52.0 million of 2021 Convertible Notes and raised $4.0 million net through its at-the-market share program.
Outlook, risks, contingencies and unusual items
- Lead-trial setback: MATrX-1, the pivotal Phase 3 trabodenoson monotherapy trial, failed its primary endpoint: it did not show statistically significant separation from placebo at every required measurement time. The company attributed this in part to a larger-than-expected placebo response and effects at four of 55 sites; analyses were ongoing. Secondary endpoint findings and the 6% dose’s reported average IOP reduction of about 4.25 mmHg did not change the primary-endpoint failure.
- Management planned to seek an FDA meeting in the first half of 2017 to discuss the results and potential next steps. The filing does not establish a confirmed path to approval or the cost and timing of further monotherapy trials.
- A Phase 2 dose-ranging trial of the trabodenoson-latanoprost fixed-dose combination was underway, with results expected in mid-2017. The company planned to start Phase 3 FDC development in 2018, subject to development progress, manufacturing, and regulatory considerations.
- Management did not expect R&D expense to increase in 2017 while it assessed the Phase 3 results. This is not a revenue or profitability forecast; the company anticipated continued losses and negative operating cash flow.
- Key risks include clinical and regulatory uncertainty, dependence on trabodenoson, additional financing needs, convertible-debt obligations and potential dilution, reliance on third-party manufacturers, reimbursement and generic competition, and the need to establish commercial capabilities.
- A stockholder class action filed January 6, 2017 alleges misleading statements and omissions regarding MATrX-1. Damages sought are unspecified; the company stated it intended to defend the case.
- Former Chief Scientific Officer William McVicar stepped down as an executive in October 2016; the company recorded approximately $0.9 million of related R&D expense.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Inotek Pharmaceuticals, not Rocket Pharmaceuticals.
- Review the complete MATrX-1 analysis, FDA feedback, and whether a feasible and funded monotherapy development plan emerged.
- Check FDC trial results, Phase 3 timing, and manufacturing and stability readiness.
- Assess cash burn against the “into 2019” runway estimate, including the costs of further trials and debt service.
- Review the $52.0 million notes’ conversion, repurchase, and maturity provisions, plus potential share dilution.
- Track the securities class action and any subsequent material developments.